Cargando…
Phase I and scintigraphy studies to evaluate safety, tolerability, pharmacokinetics, and lung deposition of inhaled GDC‐0214 in healthy volunteers
Several inflammatory cytokines that promote inflammation and pathogenesis in asthma signal through the Janus kinase 1 (JAK1) pathway. This phase I, randomized, placebo‐controlled trial assessed the pharmacokinetics and safety of single and multiple ascending doses up to 15 mg twice daily for 14 days...
Autores principales: | Zhu, Rui, Chen, Hubert, Galanter, Joshua, She, Gaohong, Cai, Fang, Durk, Matthew R., Zou, Yixuan, Chen, Liuxi, Kenny, Jane R., Vadhavkar, Shweta, Warren, Simon, Taylor, Glyn, Hwang, Olivia, Eliahu, Avi, Wynne, Chris, Owen, Ryan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9099118/ https://www.ncbi.nlm.nih.gov/pubmed/35157370 http://dx.doi.org/10.1111/cts.13240 |
Ejemplares similares
-
First‐in‐human phase 1 trial evaluating safety, pharmacokinetics, and pharmacodynamics of NLRP3 inflammasome inhibitor, GDC‐2394, in healthy volunteers
por: Tang, Fei, et al.
Publicado: (2023) -
EHMTI-0214. Headache syndromes - known to the unknown?
por: Rao, K, et al.
Publicado: (2014) -
GDC respond to crisis
Publicado: (2020) -
Mentoring, performance and the GDC
por: Saw, Mabel, et al.
Publicado: (2021) -
P02.14. Efficacy of ah shi point acupuncture on acne vulgaris
por: Son, B, et al.
Publicado: (2012)